In liver carcinoma overexpression of CD49b might be a significant independent prognostic factor.[15] In addition, in osteosarcoma CD49b expression was found to be associated with the presence of metastases and poor 5-year overall survival.[16] In glioblastoma, CD49b was highly expressed and had a negative impact on patient survival.[17]. The gene discussed is ITGA2; the disease is hepatocellular carcinoma.